Concentraciones séricas de ácido valproico en personas con epilepsia: Implicación clínica

Translated title of the contribution: Serum concentrations of valproic acid in people with epilepsy: Clinical implication

Angel T. Alvarado, Juan Cotuá, Maryori Delgado, Alexis Morales, Ana María Muñoz, César Li Amenero, María R. Bendezú, Jorge A. García, Doris Laos-Anchante, Felipe Surco-Laos, Berta Loja, Mario Bolarte-Arteaga, Mario Pineda-Pérez

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Context: Therapeutic drug monitoring (TDM) allows personalizing the dose of valproic acid in patients with epilepsy to optimize drug therapy, minimize adverse effects and detect interactions. Aims: To determine valproic acid concentrations in serum samples from people with epilepsy and to analyze its clinical implications. Methods: Cloned donor enzyme immunoassay; descriptive, cross-sectional, non-randomized, convenience recruitment study of 57 voluntary patients with epilepsy (n = 39 male, 68.42%; n = 18 female, 31.58%) aged between 19 and 62 years. After three months of treatment with valproic acid, a single blood sample was collected from each volunteer at a minimal concentration. Results: Serum drug concentrations 51.30-100.10 mg/L (SD 5.94) and level/dose 2.17-5.31 (SD 1.14) were observed. Association was shown between the dose ratio/dose of valproic acid (R2 = 0.8693; p<0.05) and the Mann-Whitney U test (p<0.05). Valproic acid monotherapy and association with carbamazepine and phenytoin are not different between treatment groups (Mann-Whitney U test: p = 0.391 > α = 0.05). Conclusions: Serum valproic acid concentrations are within the therapeutic range, and there is a significant inverse linear correlation between dose ratio/dose, which must be considered to personalize the dose and optimize the pharmacotherapeutic result.

Translated title of the contributionSerum concentrations of valproic acid in people with epilepsy: Clinical implication
Original languageSpanish
Pages (from-to)1117-1125
Number of pages9
JournalJournal of Pharmacy and Pharmacognosy Research
Issue number6
StatePublished - Nov 2022

Bibliographical note

Funding Information:
The authors thank the members of the Molecular Pharmacology Society of Peru for their participation in this study. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Publisher Copyright:
© 2022 Journal of Pharmacy & Pharmacognosy Research.


Dive into the research topics of 'Serum concentrations of valproic acid in people with epilepsy: Clinical implication'. Together they form a unique fingerprint.

Cite this